Exploration of the breast ductal carcinoma in situ signature and its prognostic implications-Reference-Cited by-同舟云学术

Exploration of the breast ductal carcinoma in situ signature and its prognostic implications

Published:2022-07-26 Issue:3 Volume:12 Page:3758-3772
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Zhang Jiao¹^ORCID,Lin Hui²³,Hou Lei¹,Xiao Hui¹,Gong Xilong¹,Guo Xuhui¹,Cao Xuchen²,Liu Zhenzhen¹^ORCID

Affiliation:

1. Department of Breast Disease, Henan Breast Cancer Center Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou China

2. The First Department of Breast Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education Tianjin China

3. Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University Taizhou China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5071

Reference53 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Breast cancer

3. Use of and Mortality After Bilateral Mastectomy Compared With Other Surgical Treatments for Breast Cancer in California, 1998-2011

4. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer

5. Ductal carcinoma in situ of breast: update 2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weighted Combination of Łukasiewicz implication and Fuzzy Jaccard similarity in Hybrid Ensemble Framework (WCLFJHEF) for Gene Selection;Computers in Biology and Medicine;2024-03

2. Update on Management of Ductal Carcinoma in Situ;Clinical Breast Cancer;2023-12

3. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma;Frontiers in Oncology;2023-01-27